

INFORMATION ONLY

Introduction of CBS Manufactured Pathogen Reduced Plasma (Apheresis Multiplasma)

Customer Letter # 2024-32

2024-09-20

Dear Colleagues:

Canadian Blood Services is excited to announce that we are working towards manufacturing pathogen-reduced plasma using the Intercept Blood System for Plasma by Cerus, the same technology currently used for platelets.

We anticipate implementing this new blood component in the summer of 2025, pending Health Canada approval. Hospitals will receive details and necessary updates for laboratory systems at least six months prior to the staggered rollout. Educational resources will be available in the coming months.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist

Sincerely,

Jody Faught Vice-President, Supply Chain